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Background: The rapidly expanding era of “omics” research is highly dependent on
the availability of quality-proven biological material, especially for rare conditions
such as pediatric malignancies. Professional biobanks provide such material, focusing
on standardized collection and handling procedures, distinctive quality measure-
ments, traceability of storage conditions, and accessibility. For pediatric malignancies,
traditional tumor biobanking is challenging due to the rareness and limited amount of
tissue and blood samples. The higher molecular heterogeneity, lower mutation rates,
and unique genomic landscapes, however, renders biobanking of this tissue even
more crucial.
Aim: The aim of this study was to test and establish methods for a prospective and
centralized biobank for infants, children, and adolescents up to 18 years of age diag-
nosed with cancer in Norway.
Methods: Obtain judicial and ethical approvals and administration through a consor-
tium, steering committee, and advisory board. Develop pipelines including SOPs for
all aspects in the biobank process, including collection, processing and storing of sam-
ples and data, as well of quality controlling, safeguarding, distributing, and transport.
Results: The childhood cancer biobanking started at Oslo University Hospital in
March 2017 and was from 2019 run as a national Norwegian Childhood Cancer Bio-
bank. Informed consent and biological samples are collected regionally and stored
centrally. Approximately 12 000 samples from 510 patients and have been included
by January 1, 2021, representing a 96% consent and participation rate among our
newly diagnosed patients.
Conclusion: A well-functioning nationwide collection and centralized biobank with
standardized procedures and national storage for pediatric malignancies has been
established with a high acceptance among families.
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1 | INTRODUCTION
Biobanks are repositories of biological samples with linked data. They
are established to collect and harvest biological material during rou-
tine activities in an organized and standardized manner and therefore
require pipelines for collection and facilities for storage of the biologi-
cal specimens.1,2 For pediatric oncology, the rapidly expanding era of
“omics” (genomics, transcriptomics, proteomics, and metabolomics)
and the impact on translational medicine is rendering the availability
of biological material for research as increasingly crucial. Precise and
effective treatment strategies based on genetic and molecular under-
standing of the diseases are increasingly being applied in pediatric
cancer treatment, aiming to improve quality of life and resulting in fur-
ther increase of survival - cure rates. Hence, the investment in such
professional collection and storage of biological material may in addi-
tion stimulate innovative biomedical development, enabling wide-
scale, and correlated clinical research.
Traditionally, tumor biobanking has been thematic and according to
cancer type.3,4 There are, however, strong arguments favoring the bio-
banking of pediatric malignancies as a collective entity. First, research
shows that pediatric malignancies display distinct differences from adult
cancers with higher molecular heterogeneity and lower mutation rates
hence warranting separate research focus.1 Second, pediatric malignan-
cies are rare, and the possibility for focus on unique genomic landscapes
in pediatric malignancies naturally disappears in larger groups of samples
where pediatric cases are greatly outnumbered. Thirdly, the limited
amount of tissue and blood samples challenging all biobanking procedures
is even more pronounced in children, where methods like needle biopsies
for tissue sampling are necessarily applied.5 A national collection of sam-
ples for the whole entity of pediatric malignancies address these concerns
by allowing for collection of larger sample sizes, and ensuring professional
tracking, processing, storage of samples, and retrieval processes. Finally,
there is an increasing demand for biological material for diagnostic pur-
poses, clinical treatment protocols and research projects, making an
F IGURE 1 Structure of the
Norwegian Childhood Cancer Biobank.
The Norwegian Childhood Cancer
Biobank is anchored in a national
consortium and based on an
agreement between the hospitals.
Each consortium participant is
responsible to legal set of agreements
regarding joint ownership and use of
biological material and data in the
biobank. Oslo University Hospital is
the responsible institution with the
main juridical liability. Each university
hospital has representatives in the
steering committee, which is
committed to follow the consortium
statues and review application for use
of samples and data from the biobank.
In addition, it is established an advisory
board, which gives their professional
assessments and advice regarding
research projects. The advisory board
is composed of experienced
researchers within the childhood
cancer field and a user representative.
The participants are invited by the
steering committee to participate for
4 years, and the composition of the
group aims to be a mix of basal
medicine and clinical knowledge
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organizational structure advantageous, enabling reuse of material and
data generated from the material. This will lead to reduced consent
fatigue, ensure good governance, increase collaboration activities among
research groups both nationally and internationally, and reduce the risk of
using the limited precious material for multiple and identical types of
analyses.6
The Norwegian Childhood Cancer Biobank (NCCB) is a prospective
biobank including infants, children, and adolescents from 0 to 18 years of
age diagnosed with cancer in Norway.7 The overall aim of the NCCB is to
stimulate and facilitate basic and translational research within childhood
cancer through a national pipeline for biobanking tumor, microbiotic, and
germline tissue at all regional childhood cancer departments and from all
children with newly diagnosed cancer in Norway, providing the basis for
advanced childhood cancer research on a national and international basis.
2 | MATERIALS AND METHODS
2.1 | Organizational structure
The NCCB project was approved by the regional ethical committee
(REC 2016/943–1) in 2016. The expansion towards national bio-
banking was organized through a national consortium (the National
Childhood Cancer Biobank Consortium) consisting of representatives
from the four regional hospitals Oslo University Hospital (OUH),
Haukeland University Hospital (HUS), St. Olavs Hospital and Univer-
sity Hospital of Northern Norway (UNN) and user representative from
the Norwegian Childhood Cancer Society. The biobank is adminis-
trated by a steering committee, and the applications for material
recovery are reviewed by a scientific advisory board (Figure 1).
2.2 | Inclusion by informed consent
Each regional hospital is responsible for including their respective
patients to the NCCB. The patient group encompasses children admit-
ted with suspected, newly diagnosed, or relapsed childhood cancer.
For patients below age 16, both parents are required to sign the
informed consent on behalf of the child. For patients between age
16 and 18, both patient and parents are required to sign. The NCCB
use different consent forms to facilitate the information given based
on the age of the child. All informed consent forms are approved by
the ethical committee (REC 2016/943–1). Only patients with
informed consent are included in the biobank. For each patient, a con-
fidential biobank ID is generated. Data describing the biological mate-
rial is registered in an electronic register (Table 1). The key link
between the biobank ID and the personal ID is kept in a separate
safety system, stored on servers for sensitive information at the four
regional centers. The participants may withdraw their consent at any
time, and because the parents are signing the consent on behalf of
the child, a renewed signed consent from the participant is required
when he/she reaches the age of 18. If the participant chooses to
withdraw the consent from the biobank, all biological material will be
destroyed, but research already performed will be kept.
2.3 | Collection of samples
Biobank samples are collected after diagnostic material has been
secured. Depending on the age and condition of the patient, samples
are retrieved either awake or in general anesthesia. Optimally 4 ml
blood is drawn into a K2EDTA VACUETTE (Greiner Bio-One, Austria)
and a serum clot activator VACUETTE (Greiner Bio-One, Austria),
heparinized bone marrow is collected into a Li-heparin VACUETTE
(Greiner Bio-One, Austria) and spinal fluid is collected into a no addi-
tive VACUETTE (Greiner Bio-One, Austria) for biobanking. In addition,
the patients are asked to give noninvasive samples as buccal swabs
(Whatman Sterile OmniSwab, GE Healthcare Life Sciences, USA) as
well as urine, feces and hair where feasible (Table 2).
2.4 | Sample processing, aliquoting, and transport
of samples
The blood samples are handled within one hour after sampling in the
laboratory according to standard operational procedures (SOP). Whole
blood from the EDTA tube (Greiner Bio-One, Austria) is aliquoted into
unique 0.5 ml matrix tubes (250 μl in each, Thermo Fisher Scientific,
USA) and the rest of the blood is centrifuged at 2500 g to collect
250 μl aliquots of plasma and 500 μl buffy coat. Serum is collected
after coagulation for minimum 30 min at room temperature and cen-
trifugation at 2500 g. Urine, bone , and spinal fluid are aliquoted into
500 μl and 250 μl aliquots and frozen at 80C.
Tumor biopsies are kept sterile and snap frozen preferably within
30–60 min after collection at the responsible Pathology Department.
The tumor tissues are stored in 1.8 ml barcoded matrix tubes (Thermo
Fisher Scientific, USA) and frozen at 80C.




ICD-10 diagnosis and diagnosis category
Comorbidity*
Metastasis*
Age and date of diagnosis
Treatment protocol and start of treatment*
Other medications*
Family history (siblings, parents)*
Vaccination program*
Attended daycare (from what age)*
*Tentatively only collected at OUH.
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All samples are transported from the regional hospitals to the
Department of Pediatric Research at OUH (Figure 1) at regular inter-
vals. The samples are transported in approved styrofoam boxes filled
with dry ice with parcel tracking and overnight express to minimize
temperature changes and ensure optimal storage conditions.
All aliquots are registered in a safety approved electronic tracking
system delivered by Laboratory Information Management System
(LIMS) (LabWare, USA). The matrix barcode on the tube (Thermo
Fisher Scientific, USA) labels each sample with an unique sample iden-
tifier, and the LIMS makes it possible to connect information such as
SOPs, collection time, additive, and thaw count to the barcode. In
addition, the system provides a storage hierarchy for tracking the ali-
quots for later analyses.
2.5 | DNA/RNA extraction
DNA and RNA are extracted at the Department of Pediatric Research
(OUH). Germline DNA from patients with solid tumors are extracted
from whole blood using spin column technology with QIAamp DNA
blood mini/midi kit (QIAGEN, Germany) and germline DNA from leu-
kemia patients are extracted from buccal swabs (GE Healthcare Life
Sciences, USA) with QIAamp Investigator Kit (QIAGEN, Germany) or
complete remission bone marrow or blood by using QIAamp DNA
blood mini/midi kit (QIAGEN, Germany).
Tumor tissue is sectioned and stained with hematoxylin and eosin
to determine tumor percentage. DNA and RNA are extracted from tis-
sue with >40% tumor using AllPrep DNA/RNA mini kit (QIAGEN,
Germany).
Quality control is performed by measuring the optical density
while DNA and RNA purity is determined based on the 260/230 and
260/280 ratio, using a NanoDrop spectrophotometer (ND-1000,
Thermo Scientific, USA). In addition, fluorescence measurements are
used to determine the concentration and yield of DNA by a Qubit
DNA BR assay (Thermo Fisher Scientific, USA) and RNA by a Qubit
RNA BR Assay (Thermo Fisher Scientific, USA) on a Qubit 4 Fluorome-
ter (Invitrogen, Thermo Fisher Scientific, USA). Based on the Qubit
measurements, 500 ng DNA/RNA is aliquoted into six barcoded
matrix tubes (Thermo Fisher Scientific, USA), registered in the LIMS
system and stored at 80C.
2.6 | Storage
All biological samples and the extracted DNA and RNA samples are
stored in monitored 80C ultra-freezers located in monitored stor-
age facilities at the Norwegian Institute of Public Health. The freezers
are connected to external alarm systems and temperatures are logged
routinely to assure stable storage temperature and good preservation
of the quality of the samples. The freezers are connected to an emer-
gency electrical system to provide backup power and the facility pro-
vides backup freezers, which constitutes 10% of the total freezer
capacity.
2.7 | Quality assurance and quality control
procedures
Each sample is handled according to SOPs, which are regularly
reviewed and updated. Connected to every patient is a flowchart,
F IGURE 2 Norwegian Childhood Cancer Biobank work flow.
Consent, inclusion, and sample collection according to Table 2 are
performed at all four region hospitals. All samples are transported to
the central lab at OUH for electronical registration and further
processing. The samples are either stored at longtime storage or sent
directly to research projects. *Surplus material are transported back to
NCCB for reuse in research. Created with BioRender.com













*Tentatively only collected at OUH.
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which is filled out by responsible study nurse and authorized labo-
ratory personnel. Time point of sampling and centrifugation is
noted, in addition to cold ischemia time and freezing point for
tumor tissue. Deviations from the SOPs are noted in the flowchart
and registered in the LIMS. In addition to SOPs and the flowchart,
NCCB has an ongoing study investigating changes in quality and
quantity of DNA based on time to freeze and longtime storage of
whole blood. These results will be presented in a coming
manuscript.
3 | RESULTS
Childhood cancer biobanking started at the OUH in March 2017 and
expanded to include children on a national basis from January 2019
(Figure 2). The infrastructure of sample collection has been endorsed
and supported at all four regional pediatric clinics, with the ambition
of integrating sampling pipelines into the clinical ward as standard
procedures. Tumor tissue, germline tissue (blood samples or buccal
swabs), microbiotic tissue, and hair samples are all collected at time
of diagnosis, in addition to blood samples and tumor tissue in case of
relapsed disease. Health outcome information may be made avail-
able for all patients through linkage to the hospital journals or Nor-
wegian national health registries upon approval by ethical
committee.
3.1 | Status to date
As of January 1, 2021, a total of 510 patients have been included
and approximately 12 000 samples have been processed and
stored in the biobank (Table 3). Of all patients invited to contribute
to the NCCB biobank, 96% have consented to participate. Feasibility
has been shown regarding collection of informed consent and
biological samples locally, regular transportation of material to
OUH, and central treatment of samples according to standardized
procedures.
Approximately 34% of the patients are diagnosed with leukemia,
18% have cancer related to the central nerve system (CNS), and 34%
are diagnosed with solid tumors outside CNS. The remaining 13% are
diagnosed with nonmalignant diagnoses (Figure 3). Diagnoses
included in the groups and the number of patients diagnosed are pres-
ented in Table 3.
3.2 | Impact on research
Material from about one third of all consented donors has been
involved in eight different research projects. Ongoing studies are con-
tinuously published on our web page, including the name, responsible
PI and a short description of the project (https://www.ous-research.
no/home/childhoodcancerbiobank/Projects/19154). The involved
projects cover a wide range from basic to translational research stud-
ies (e.g.8).
TABLE 3 Diagnoses of the first 500 patients collected for NCCB









Germ cell tumors <5
Hepatic tumors <5





Other tumors related to CNS <5
Leukemia 35
Acute lymphocytic leukemia 29
Acute myeloid leukemia 5
Chronic myeloid leukemia <5
Other 13
Other noncancer diagnoses 5
Nonmalignant tumors 5
Langerhans cells histiocytosis <5
Myelodysplastic syndrome <5
Anemia <5
Enlarged lymph nodes <5
Note: The bolded values represent the number of patients in the main
tumor groups; solid tumors, CNS tumors and liquid tumors.
Abbreviation: CNS, central nerve system.
F IGURE 3 Diagnostic distribution of patients in the Norwegian
Childhood Cancer Biobank. All included cancer diagnoses in NCBB are
categorized into solid tumors, central nerve system (CNS) tumors, or
leukemia, while nonmalignant diagnoses are placed in the category
“other.” More information about the content of the different parts is
listed in Table 3
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In addition, NCCB facilitates storage and coordination of
transporting samples to international collaborative childhood cancer
treatment studies. As biological research is increasingly becoming part
of international childhood cancer treatment studies, and approxi-
mately 50% of our children are included in such studies, the NCCB
has become an important part of the infrastructure needed to enable
participation in these crucial studies.
4 | DISCUSSION
Biobanking is an essential tool for medical research, in particular for
diseases with few new cases per year. The ambition of the NCCB is to
be a modern biobank, and actively facilitate and assist fundamental
and applied clinical research by enabling access to biological material
according to scientific requirements. The biobank aims to collect bio-
logical samples from all children and adolescents with newly diag-
nosed cancer in Norway. With a 96% inclusion rate, the invited
participants have exhibited a very positive attitude regarding contri-
bution towards the NCCB.
The importance of childhood cancer biobanking is becoming
increasingly evident through other large-scale pediatric biobank pro-
jects. The American Pediatric Cancer Genome project was launched in
2010 and demonstrated a significant difference in the spectrum of
childhood cancers compared to adult cancers, as well as a large geno-
mic heterogeneity between childhood cancers.9 The awareness of the
differences between adult and childhood cancer, and the heterogene-
ity between pediatric cancer types, strengthens the importance of
large-scale collective biological sampling from this vulnerable and het-
erogeneous group of patients.
The NCCB aims to include all Norwegian pediatric patients with
malignancies, as well as a varied range of samples per donor to cover
various research fields and interests. This is a different approach from
other Norwegian cancer biobanks such as the population based Janus
Serum Biobank and the clinically based prospective Breast Cancer
Biobank and Prostate Biobank, examples of adult biobanks related to
cancer established in Norway. The prospective Breast Cancer Biobank
and the Prostate biobank are cancer specific thematic biobanks con-
sisting of donors from Western Norway and Oslo-area respectively,
while the Janus Serum bank collects blood tissue only from population
based donors.3,10–12 While these larger biobanks specialize on collect-
ing and storing blood and/or tumor samples, the NCCB aims to collect
as many relevant sample types as possible from our rarer number of
cases. The collection of urine, feces, and hair opens the possibility to
investigate environment exposures in childhood cancer care among
others.
The inclusion rate of patients in the NCCB is extremely high, and
represents the childhood cancer incidences in Norway given by the
National cancer registry.13 A total of 35% of all participants included
in NCCB are diagnosed with leukemia, which is in line with the
expected national distribution of childhood cancer diagnoses based
on numbers from 1985 to 2018 from the Norwegian Cancer
Registry's 2018 Annual Report13 (Figure 3). The distribution of 80% of
patients diagnosed with acute lymphocytic leukemia (ALL) and 20%
diagnosed with acute myogenic leukemia within the leukemia group is
also in agreement with the numbers from the Norwegian Cancer Reg-
istry Report.13
Another strength of the NCCB is the close collaboration
between the different departments and among the different hospi-
tals. Centralization of treatment and storage of samples has posed
challenges of both logistic and collaborative nature, as all parts are
aware of the value and scarcity of biological material. However,
the engagement of pediatric oncologists, pathologists, nurses, and
scientists that are clinically involved in the care and treatment of
the pediatric patients, and the development of a national adminis-
trative steering group, made the national biobank endeavor possi-
ble. This teamwork of professionals that are close to the pediatric
wards is also the basis for further translational projects, including
the individualized therapy for relapsed malignancies in childhood
study,8 using the logistics of inclusion and sampling provided by
the NCCB.
From the beginning, the NCCB has chosen to open for sample
release to ethically approved prospective studies, and to facilitate stor-
age and release of research samples to clinical treatment protocols and
add-on studies. Projects approved by the Norwegian Regional Ethics
committee (REC) may apply for material from NCCB by submitting an
application form provided on our homepage (www.ous-research.no/
barnekreftbiobank/docs/Barnekreftbiobank Application for Data and
Biological Material vs 1 61.docx and www.ous-research.no/barnek
reftbiobank/docs/Barnekreftbiobank Application for use of Gene
ral Consent.docx). The NCCB steering committee evaluates and
approves the submitted proposals based on scientific impact and
demanded infrastructure and resources.
This strategy is based on our aim to facilitate collaborations and
research within childhood cancer, and ensure that samples are being
used in research. Furthermore, the NCCB has had a close collabora-
tion with the Swedish Childhood Tumor Bank during the initial
phase.14 The protocols of the NCCB, the Swedish Childhood Tumor
Bank and other relevant childhood cancer biobanks show many simi-
larities with collection of germline and tumor material, but may differ
in terms of additional sampling and up front analysis. The NCCB
assembles a very broad selection of collected materials, but has not
prioritized to perform many up-front analyses (i.e., sequencing).
SOPs have been developed to handle germline and tumor mate-
rial similar to their protocols, and consequently, data from both
biobanks could be merged to increase the number of samples for ret-
rospective research in the future. This kind of international collabora-
tion opens up new aspects - and evolve the old ones - for biomedical
researchers, clinicians, and industrial partners. Contemporarily,
biobanks tend to organize themselves into international networks to
increase the impact of research activities. Biobanking and Biomolecu-
lar Resources Research Infrastructure was one of the first European
research infrastructure projects funded by the European Commission
in January 2011.15 Another significant organization is EuroBioBank,
with 26 members and samples combined with data available in the
online catalogue.16 The NCCB will pursue to establish novel
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collaborations with national and international networks in the future
and to continue to promote research collaborations in national and
Nordic working groups, such as the Nordic organization for Pediatric
Hematology and Oncology.
A major challenge for a childhood cancer biobank is the heteroge-
neity between types of childhood cancer. This might necessitate col-
lection of samples across different clinical units, pathology
departments, and will involve many different disciplines. For example
at OUH, CNS tumor patients are diagnosed at a different department
than other childhood cancer patients, making standardized inclusion
logistically more challenging. This may explain the lower inclusion rate
of CNS patients (20% vs. the 26% patients expected according to the
Norwegian Cancer Registry Report).13
The NCCB is operating in compliance with current biobanking
standards, but has not yet been formally certified according to ISO
standards as the accreditation system for biobanks is still under revi-
sion. It is planned to implement ISO 20387:2018 standards for bio-
banking with accreditation for the specific biobank procedures in the
future. This will be a confirmation of the competence of the biobank
and state appropriate quality of both biological samples and data
collections.17
In conclusion, the NCCB provides a wide range of biological sam-
ples from all consenting childhood cancer patients in Norway, according
to standardized procedures, ensuring proper quality and quantity of the
stored material. In addition to collecting and storing samples for future
research, the NCCB is actively supporting both translational projects as
well as more basic research projects. All project using samples from
NCCB are listed and described in further detail on the public webpage
of NCCB (https://www.ous-research.no/barnekreftbiobank/).
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